1 / 1

Investigation of C1 Inhibitors and Anti-C5a Therapeutics in Factor B-/- Mice Models

This study explores the role of complement component C1 inhibitors, including Crry-Ig, sCR1, and rVCP, in Factor B-deficient mice. It specifically examines the effects of monoclonal antibody mAb1379 targeting C5a and the use of antagonists against receptors CD88 (C5aR) and C5. Our findings highlight the therapeutic potential of these antibodies to modulate immune responses and may lead to new treatments for diseases involving complement dysregulation.

paco
Télécharger la présentation

Investigation of C1 Inhibitors and Anti-C5a Therapeutics in Factor B-/- Mice Models

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. C1-Inh C3 convertase inhibitors (Crry-Ig, sCR1, rVCP) Factor B-/- mice mAb1379 C5a antagonists Anti-C5aR (CD88) Abs Anti-C5 Abs

More Related